Plus Therapeutics

PSTV

Market cap $28.1M

Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring

Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript

Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company focused on central nervous system (“CNS”) cancers, today provides a comprehensive business update. Notably, the Company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to CNSY, effective August 3, 2026.

HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to 126 million people.

Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans

Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending shares of the Nasdaq-listed company up 8.7% to $5.89 Thursday. CNSide Diagnostics' Houston-based clinical laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, and overall laboratory management.

HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program. The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation.

Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making  reducing healthcare costs by 40%

Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, today announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies (“Ephemeral”) to deliver a unique AI execution platform for CNS oncology. The AI execution platform is designed to integrate, organize, and derive actionable intelligence from longitudinal therapeutic, diagnostic and bioinformatic data sets generated across Plus' CNS oncology technology programs.

Plus Therapeutics (PSTV) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to a loss of $14 per share a year ago.